Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 26 member 2 (SLC26A2) is a widely expressed cell membrane protein that functions primarily as an electroneutral sulfate/chloride antiporter, facilitating the uptake and exchange of inorganic sulfate and other anions across the plasma membrane[1][2][4]. It is crucial for the sulfation of proteoglycans, essential molecules for cartilage structure during development, and thus vital for normal cartilage and bone formation[4]. Pathogenic mutations in SLC26A2 severely disrupt proteoglycan sulfation, resulting in inherited skeletal dysplasias with phenotypes ranging from lethal achondrogenesis type 1B and atelosteogenesis type 2 to less severe diastrophic dysplasia and multiple epiphyseal dysplasia[1][2][3][4]. The gene is also implicated in non-congenital disease contexts such as Crohn’s disease (where expression is upregulated) and certain cancers (where repression promotes proliferation and TRAIL-resistance)[2]. SLC26A2 is considered an important therapeutic target, particularly in modeling and understanding the cellular defects in chondrodysplasia and exploring new therapies[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 26 member 2 (SLC26A2).